Paper Details

  1. Home
  2. Paper Details

Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes.

Author: ArteagaE, CárdenasI, HormazaP, OestreicherE, VillasecaP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ethinylestradiol (EE) combined with cyproterone acetate (CPA) significantly decreases the free androgen index, increases sex hormone binding globulin, and improves lipid profile in women with PCOS, but does not significantly affect carbohydrate metabolism.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Ethinylestradiol (EE) combined with the antiandrogenic progestin cyproterone acetate (CPA) is a possible treatment in polycystic ovary syndrome (PCOS). We investigated the impact of EE/CPA on lipid and carbohydrate metabolism in women with PCOS,who were otherwise healthy. METHOD: The 31 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/13625180400007751

データ提供：米国国立医学図書館（NLM）

Ethinylestradiol/cyproterone Acetate in Polycystic Ovary Syndrome: Lipid and Carbohydrate Changes

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that affects millions of women worldwide. This study delves into the impact of a specific hormonal therapy, ethinylestradiol (EE) combined with cyproterone acetate (CPA), on lipid and carbohydrate metabolism in women with PCOS. The researchers compared the effects of this treatment to a control group receiving a different hormonal therapy, medroxyprogesterone acetate (MPA). Their findings offer valuable insights into the potential benefits and risks of EE/CPA therapy in managing PCOS, examining its impact on hormonal balance, lipid profiles, and carbohydrate metabolism.

A New Oasis in the Desert of PCOS Treatment

The study found that EE/CPA therapy led to significant improvements in hormone parameters associated with hyperandrogenism, a key feature of PCOS. It also resulted in favorable changes in lipid profiles, with a decrease in low-density lipoprotein (LDL) cholesterol and an increase in high-density lipoprotein (HDL) cholesterol. These findings suggest that EE/CPA therapy might offer potential benefits for managing some of the metabolic complications associated with PCOS. However, the researchers also noted an increase in triglyceride levels, highlighting the need for careful monitoring and management of this potential side effect.

Navigating the Complexities of PCOS Management

The study highlights the potential benefits of EE/CPA therapy for women with PCOS, suggesting that it may improve hormonal balance and lipid profiles. However, it's important to remember that this study was limited in scope and further research is needed to fully understand the long-term effects and risks of this treatment. This study serves as a reminder that the desert of PCOS management is vast and complex, requiring ongoing exploration and innovation to develop effective solutions for all women affected by this condition.

Dr.Camel's Conclusion

This study offers a glimpse into the potential benefits of EE/CPA therapy for PCOS. However, it's important to navigate the desert of PCOS management with caution and seek guidance from healthcare professionals to ensure individualized and effective treatment.

Date :
  1. Date Completed 2005-03-10
  2. Date Revised 2019-11-09
Further Info :

Pubmed ID

15697105

DOI: Digital Object Identifier

10.1080/13625180400007751

Related Literature

Article Analysis
・Effective treatment of polycystic ovary syndrome
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.